Understand the source comparison
Immune Support Peptides 2026 Update: Synthesis Comparison
Solid-Phase Peptide Synthesis (pre-2025) RP-HPLC only (≥95% by UV) Not routinely tested 8–15% batch variance in bioactivity Adequate for early research but insufficient for reproducible immunology studies Liquid-Phase Peptide Synthesis (pre-2025) RP-HPLC + ami
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Solid-Phase Peptide Synthesis (pre-2025)
- RP-HPLC only (≥95% by UV)
- Not routinely tested
- 8–15% batch variance in bioactivity
- Adequate for early research but insufficient for reproducible immunology studies
- Liquid-Phase Peptide Synthesis (pre-2025)
- RP-HPLC + amino acid analysis
- LAL testing if requested
- 5–10% batch variance
- Better than SPPS but sequence truncations still occurred
- Solid-Phase Synthesis with 2026 Standards
- RP-HPLC + MALDI-TOF mass spec
- LAL mandatory (<0.5 EU/mg)
- <3% batch variance
- Current gold standard for research-grade immune peptides
- cGMP Synthesis (clinical-grade)
- Full ICH Q6B analytical suite
- Endotoxin <0.25 EU/mg + pyrogenicity testing
- <1% batch variance
- Required for clinical trials; cost 3–5× higher than research-grade